Savara to Present at the Jefferies London Healthcare Conference
- Participation in prestigious healthcare conference indicates company's commitment to investor engagement and industry visibility.
- None.
About Savara
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. (X, formerly known as Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).
View source version on businesswire.com: https://www.businesswire.com/news/home/20231108029896/en/
Savara Inc. IR & PR
Anne Erickson
anne.erickson@savarapharma.com
(512) 851-1366
Source: Savara Inc.
FAQ
What is the event Savara Inc. (SVRA) will participate in?
Where can I watch the live webcast of the fireside chat?